Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease
Open Access
- 1 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2) , fcaa152
Abstract
Serum creatinine and C-reactive protein have been proposed as potential biomarkers for neurodegenerative diseases, including amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease. However, longitudinal studies investigating temporal patterns of these biomarkers, including the phase before diagnosis, are rare. We performed a case–control study including all newly diagnosed patients with amyotrophic lateral sclerosis (N = 525), multiple sclerosis (N = 1815) or Parkinson’s disease (N = 3797) during 2006–2013 in Stockholm, Sweden, who participated in the Stockholm CREAtinine Measurements (SCREAM) project. For each case, we randomly selected up to five controls from SCREAM that were individually matched to the case by age, sex and county of residence (N = 2625 for amyotrophic lateral sclerosis, N = 9063 for multiple sclerosis and 18 960 for Parkinson’s disease). We collected for both the cases and the controls testing results of serum creatinine and C-reactive protein performed by healthcare providers in Stockholm during the study period. Median levels of creatinine and C-reactive protein were visualized using locally weighted smoothing curves among cases and controls. A linear mixed model was also applied to explore temporal changes within an individual. Compared to controls, patients with amyotrophic lateral sclerosis had lower levels of creatinine from 2 years before diagnosis onwards. In contrast, patients with amyotrophic lateral sclerosis had lower levels of C-reactive protein before diagnosis but higher levels after diagnosis, compared to controls. Focusing the 2 years before to 2 years after diagnosis, patients with amyotrophic lateral sclerosis displayed statistically significantly decreasing level of creatinine from 1 year before diagnosis until 2 years after diagnosis, whereas increasing level of C-reactive protein from diagnosis until 2 years after diagnosis. There were no similar patterns noted among patients with multiple sclerosis or Parkinson’s disease, or the controls of the three patient groups. Patients with amyotrophic lateral sclerosis display distinct temporal patterns of creatinine and C-reactive protein before and after diagnosis, compared to amyotrophic lateral sclerosis-free controls or patients with multiple sclerosis and Parkinson’s disease.Keywords
Funding Information
- Swedish Research Council (2019-01088, 2019-01059)
- Karolinska Institutet
This publication has 46 references indexed in Scilit:
- Validation of multiple sclerosis diagnoses in the Swedish National Patient RegisterEuropean Journal of Epidemiology, 2019
- Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s DiseaseBioMed Research International, 2018
- Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson DiseaseCognitive and Behavioral Neurology, 2016
- An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosisNeurological Sciences, 2014
- Mitochondrial Dysfunction in Neurodegenerative DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literatureJournal of Cachexia, Sarcopenia and Muscle, 2012
- Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative DisordersCurrent Alzheimer Research, 2012
- Bone and mineral metabolism in older adults with Parkinson's diseaseAge and Ageing, 2009
- Utility of cystatin C to monitor renal function in duchenne muscular dystrophyMuscle & Nerve, 2009
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical researchEuropean Journal of Epidemiology, 2009